Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Medtronic Cardiovascular
Dana-Farber Cancer Institute
Galapagos NV
Merck Sharp & Dohme LLC
BeOne Medicines
University of Florida
University of Washington
National Institutes of Health Clinical Center (CC)
Genmab
Genmab
Novartis
Thomas Jefferson University
Actinogen Medical
Big Ten Cancer Research Consortium
Regeneron Pharmaceuticals
Cognito Therapeutics, Inc.
University of Texas at Austin
Hoffmann-La Roche
H. Lee Moffitt Cancer Center and Research Institute
Hennepin Healthcare Research Institute
University of Michigan Rogel Cancer Center
Celgene
Fred Hutchinson Cancer Center
City of Hope Medical Center
Incyte Corporation
Swedish Orphan Biovitrum
M.D. Anderson Cancer Center
Washington University School of Medicine
Fondazione Italiana Linfomi - ETS
Sana Biotechnology
City of Hope Medical Center
Brigham and Women's Hospital
National Cancer Institute (NCI)
Celgene
University of Washington
Memorial Sloan Kettering Cancer Center
Immunitas Therapeutics
Ohio State University Comprehensive Cancer Center
Acerta Pharma BV
Regeneron Pharmaceuticals
Gilead Sciences
City of Hope Medical Center
Ohio State University Comprehensive Cancer Center
Barbara Ann Karmanos Cancer Institute
University of Nebraska